Programme Thesis
This NIH R01 program funds the discovery and validation of novel in vivo chemical probes for targets in the nervous system, aiming to accelerate the development of tools for studying neural function and disease. It exists to bridge the gap between basic neuroscience and therapeutic development by supporting high-risk, high-reward projects that produce selective, brain-penetrant small molecules or biologics.
Selection Criteria
- Significance: Does the project address an important problem in neuroscience? Will the probes enable new discoveries?
- Investigator(s): Are the PI and team well-suited? For early-stage investigators, is there strong mentorship and institutional support?
- Innovation: Does the project propose novel targets, screening strategies, or chemical biology approaches?
- Approach: Are the experimental design, methods, and analyses rigorous and feasible? Includes validation in relevant in vivo models.
- Environment: Does the scientific environment contribute to the likelihood of success? Includes access to core facilities, collaborators, and institutional commitment.
- Scoring rubric: 1-9 (1=exceptional, 9=poor) on each criterion; overall impact score determines funding priority.
- Eligibility: Applicant must be a U.S. institution/organization; foreign components allowed but must demonstrate unique expertise or resources not available in the U.S.
Past Winners / Cohort Profiles
Typical winners are established U.S.-based academic labs (e.g., at Harvard, Stanford, UCSF, NIH intramural) with strong track records in medicinal chemistry, pharmacology, and neuroscience. Examples include projects developing PET tracers for neuroinflammation, selective modulators of GPCRs or ion channels, and chemical probes for epigenetic targets in the brain. Early-stage investigators often succeed with strong preliminary data and a clear translational plan.
Ideal Candidate Fingerprint
A mid-career or senior PI at a U.S. research university with a proven record in chemical biology and neuroscience, leading a multidisciplinary team including medicinal chemists, pharmacologists, and behavioral neuroscientists. The applicant should have preliminary data on target engagement, brain penetration, and selectivity, plus a clear plan for in vivo validation and dissemination of the probe to the community.
Recommended Framing
Eniola should partner with a U.S.-based academic collaborator (e.g., Kent Berridge at Michigan or Samuel Gershman at Harvard) who can serve as the PI on the R01, with Eniola as a key personnel or co-investigator. His CCT model and computational platform (IMPRINT, TOPOLOGIX) provide a unique, innovative angle for designing chemical probes that disrupt reward-memory consolidation in addiction—a novel target space not covered by existing probes. Emphasize the LMIC/Nigeria angle as a strength for global health impact and diversity, and leverage his endorsements to demonstrate scientific credibility.
Watch Out
Eniola is not eligible as a direct applicant because he is not affiliated with a U.S. institution; the R01 requires a U.S.-based applicant organization. He lacks a PhD or MD, which may raise concerns about his ability to lead the project independently, though this can be mitigated by the U.S. PI. No preliminary in vivo data on chemical probes—only computational and in silico validation. The deadline is March 2027, which is tight for building a collaboration and generating preliminary data.